/Isolated Recombinant Oncolytic Vaccinia Viruses, Pharmaceutical Compositions And Uses Thereof For Drugs For Treatment Of Tumors And/or Cancers
Abstract
The disclosure provides a method for treating sarcoma by administering a therapeutically effective amount of an isolated recombinant oncolytic vaccinia virus. The isolated recombinant oncolytic vaccinia virus is functionally deficient in the TK gene and the VGF gene, and comprises an exogenous IL-21 gene integrated into its genome, wherein the recombinant oncolytic vaccinia virus is capable of expressing the exogenous IL-21 gene in tumor cells. The isolated recombinant oncolytic vaccinia virus is well tolerated and safe, and can have prominent efficacy in patients with sarcoma, and additionally can effectively initiate systemic immune activity.
Full Text
What is claimed is:
The disclosure provides a method for treating sarcoma by administering a therapeutically effective amount of an isolated recombinant oncolytic vaccinia virus. The isolated recombinant oncolytic vaccinia virus is functionally deficient in the TK gene and the VGF gene, and comprises an exogenous IL-21 gene integrated into its genome, wherein the recombinant oncolytic vaccinia virus is capable of expressing the exogenous IL-21 gene in tumor cells. The isolated recombinant oncolytic vaccinia virus is well tolerated and safe, and can have prominent efficacy in patients with sarcoma, and additionally can effectively initiate systemic immune activity.
Timeline
Filed
05/22/2026Published
09/10/2026Granted
Not AvailableIPC Codes(3)
A61K 48/00:Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 38/20:Interleukins
A61P 35/00:Antineoplastic agents